NDAORALTABLETPriority Review
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
5/8 — Partial
Priority Review
RUBRACA (rucaparib) by Adienne Pharma and Biotech. Approved for ovarian cancer, fallopian tube cancer, primary peritoneal cancer. First approved in 2016.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUBRACA (rucaparib) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor approved by the FDA on December 19, 2016. Data on specific indications is not available in the provided dataset. The product is currently in peak lifecycle stage, indicating established market presence and commercial maturity.
$0.0BPart D
9.3 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on RUBRACA at Adienne Pharma and Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.